CHALLENGES IN PULMONARY DRUG DELIVERY Low Efficiency of inhalation system Aerosol system should have to produce optimum size particles because they are too small, they will be exhaled. If the particles are too large, they affects on the oropharynx and larynx. (0.5-1mm) Less drug mass per puff To get adequate effect with the pulmonary drug delivery practical delivery of many drug which require milligram doses but With most existing systems, the total amount of drug per puff delivered to the lower respiratory tract is too low less than 1000 mcg. Poor formulation stability for drug Most traditional drugs are crystalline, in the case of corticosteroids, and highly moisture sensitive drugs are unstable. Improper dosing reproducibility Reason for Poor dosing reproducibility like worsening of diseases', problem in device, un stabality of formulation. AEROSOLS - Acrosol preparations are stable dispersions or suspensions of solid material and liquid droplets in a gaseous medium. The drugs delivery by acrosols is deposited in the airways by:gravitational sedimentation inertial impaction, and diffusion. Mostly larger drug particles are deposited by first two mechanisms in the airways, while the smaller particles get their way into the peripheral region of the lungs by following diffusion. - There are three commonly used clinical aerosols: 1. Jet or ultrasonic nebulizers. 2. Metered-dose Inhaler (MDI) 3. dry-powder inhaler (DPD) The basic function of these three completely different devices is to generate a drug -containing acrosol cloud that contains the highest possible fraction of particles in the desired size range.

Question

CHALLENGES IN PULMONARY DRUG DELIVERY Low Efficiency of inhalation system Aerosol system should have to produce optimum size particles because they are too small, they will be exhaled. If the particles are too large, they affects on the oropharynx and larynx. (0.5-1mm) Less drug mass per puff To get adequate effect with the pulmonary drug delivery practical delivery of many drug which require milligram doses but With most existing systems, the total amount of drug per puff delivered to the lower respiratory tract is too low less than 1000 mcg. Poor formulation stability for drug Most traditional drugs are crystalline, in the case of corticosteroids, and highly moisture sensitive drugs are unstable. Improper dosing reproducibility Reason for Poor dosing reproducibility like worsening of diseases', problem in device, un stabality of formulation. AEROSOLS - Acrosol preparations are stable dispersions or suspensions of solid material and liquid droplets in a gaseous medium. The drugs delivery by acrosols is deposited in the airways by:gravitational sedimentation inertial impaction, and diffusion. Mostly larger drug particles are deposited by first two mechanisms in the airways, while the smaller particles get their way into the peripheral region of the lungs by following diffusion. - There are three commonly used clinical aerosols: 1. Jet or ultrasonic nebulizers. 2. Metered-dose Inhaler (MDI) 3. dry-powder inhaler (DPD) The basic function of these three completely different devices is to generate a drug -containing acrosol cloud that contains the highest possible fraction of particles in the desired size range.

Answer 1

Pulmonary drug delivery is a complex field with several challenges that need to be addressed for effective treatment. Here’s a detailed look at the challenges and some insights into aerosol systems used in pulmonary drug delivery:### Challenges in Pulmonary Drug Delivery1. **Low Efficiency of Inhalation Systems:** - **Particle Size:** The efficiency of drug delivery via inhalation largely depends on the particle size of the aerosol. Particles need to be within an optimal size range (typically 1-5 micrometers) to reach the lower respiratory tract effectively. Particles smaller than this range may be exhaled, while larger particles tend to deposit in the upper airways, such as the oropharynx and larynx.2. **Less Drug Mass per Puff:** - Many drugs require milligram doses for therapeutic efficacy, but current inhalation systems often deliver less than 1000 micrograms per puff to the lower respiratory tract. This necessitates multiple puffs or higher concentrations, which can be inefficient and inconvenient for patients.3. **Poor Formulation Stability:** - Drugs used in inhalation therapies, like corticosteroids, are often crystalline and sensitive to moisture, leading to stability issues. This instability can affect the drug's efficacy and shelf life.4. **Improper Dosing Reproducibility:** - Variability in dosing can arise from device malfunctions, formulation instability, or patient-related factors such as disease progression. Consistent dosing is crucial for maintaining therapeutic levels and managing conditions effectively.### Aerosol Systems in Pulmonary Drug DeliveryAerosols are a key component of pulmonary drug delivery, providing a means to disperse medication in a gaseous medium. The deposition of these aerosols in the lungs occurs through mechanisms such as gravitational sedimentation, inertial impaction, and diffusion.#### Types of Clinical Aerosols:1. **Jet or Ultrasonic Nebulizers:** - These devices convert liquid medication into a fine mist using compressed air (jet nebulizers) or ultrasonic waves (ultrasonic nebulizers). They are particularly useful for patients who have difficulty using inhalers.2. **Metered-Dose Inhalers (MDIs):** - MDIs deliver a specific amount of medication in aerosol form with each actuation. They are portable and convenient but require proper technique to ensure effective delivery.3. **Dry-Powder Inhalers (DPIs):** - DPIs deliver medication in powder form and rely on the patient's inhalation effort to disperse the drug. They eliminate the need for propellants and are breath-actuated, making them easier to use for some patients.Each of these devices aims to generate an aerosol cloud with particles in the desired size range to maximize deposition in the target areas of the lungs. Addressing the challenges in pulmonary drug delivery involves optimizing these devices and formulations to improve efficiency, stability, and reproducibility.

Soru

Çözüm

Cevap